I think that the company will eventually be bought out. I am not a professional but follow the industry.
It's a solid company with growing revenues in an emerging industry. The stock price is flat. I am holding.
Down yesterday because they had to halt a trial on their kidney drug. There were problems.
KKR was recommended by Leon Cooperman, Omega Advisors, on CNBC. This could be one reason for the spike.